GoldenSite™
best-in-class therapies through
radically optimized protein conjugation
for next-generation treatments.
GoldenSite™
best-in-class therapies through
radically optimized protein conjugation
for next-generation treatments.
“Effective treatments that let
patients continue living their lives,
created by passionate people
through boundary-pushing science.”
HOW IT WORKS
science
Our unique differentiators:
- GoldenSite™: Every site in a protein available for site-specific conjugation. Find your GoldenSite™ for best conjugate performance.
- Perfect definition: Lighting-fast click-chemistry enables >99% conjugation at any site. Perfect homogeneity, perfect peace-of-mind.
- Smart chemistry. Simple manufacturing: No catalyst, no enzyme needed. Simply purify, conjugate and done.
What we are aiming for:
our benefit for developers
Enhance your drugs therapeutic window through
site optimization that achieves unconjugated
antibody-like biophysical profiles, enabling
higher dosing with reduced toxicity.
De-risk clinical development with
conjugates showing no increased
hydrophobicity, self-interaction, or
polyreactivity compared to naked
antibodies – predicting superior
pharmacokinetics and safety.
Leverage AI-ready datasets from systematic
site profiling to predict optimal conjugation
positions for new targets and payloads.
our benefit for patients*
Experience reduced side effects from ADCs
designed with optimized conjugation
sites that minimize off-target toxicity
and treatment-related adverse events.
Receive more potent therapies as
improved therapeutic windows allow
physicians to administer higher,
more efficacious amounts without
increased safety concerns:
Stay on treatment longer with better-
tolerated therapies reducing the substantial
discontinuation rate seen with current ADCs
due to adverse events.
*Disclaimer: While our preclinical data strongly
suggests these patient advantages, VALANX techn-
ology has not yet entered clinical trials. These
benefits represent our scientific hypothesis based
on laboratory evidence and established ADC
development principles.
PEOPLE
meet the team
the experts enabling the next
generation of drug-conjugates
Management
Michael Lukesch
CEO & FounderMichael Lukesch
CEO & Founder
Georg Altenbacher
CBO & Co-FounderGeorg Altenbacher
CBO & Co-Founder
Klaus Orlinger
Chief Scientific OfficerKlaus Orlinger
Chief Scientific OfficerCompany Board
Michael Boehler
Michael Boehler
Alexander Schwartz
Alexander Schwartz
Ingo Nagler
Ingo Nagler
Urs Spitz
Urs Spitz
Team
Maximilian Winkler
ScientistMaximilian Winkler
Scientist
Adriana Fink
Lab SupportAdriana Fink
Lab Support
Alejandro Puchol
ScientistAlejandro Puchol
Scientist
Andrés Magán García
Principal ScientistAndrés Magán García
Principal Scientist
Katarina Belačić
Project Lead R&DKatarina Belačić
Project Lead R&D
Lea Leitner
ScientistLea Leitner
Scientist
Nikolaus Kienzl
Scientist DownstreamNikolaus Kienzl
Scientist Downstream
Marta Deneha
Marketing ManagerMarta Deneha
Marketing Manager
David Alejandro Peña
Head of UpstreamDavid Alejandro Peña
Head of UpstreamJOIN US
careers
Scientist Upstream Process Development (m/f/x)
This role is ideal for a dynamic, hands-on scientist eager to drive the translation of research processes starting from stable cell line generation through to technology transfer for GMP-compliant manufacturing. The successful candidate will develop, optimize, and scale upstream processes for antibody and antibody-drug conjugate (ADC) production in a fast-paced, collaborative biotechnology environment.
IN PROCESS
pipeline
GoldenSite™ – enabled next generation protein-drug-conjugates
PROUDLY FUELED BY
investors and funding agencies
